Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.

ABSTRACT:

Introduction

Reliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the relation between BMI variation and outcomes in metastatic breast cancer (mBC) patients treated with everolimus.

Results

we found a linear correlation between everolimus exposure duration and BMI/weight decrease. Patients exhibiting >2 kg weight loss or >3% BMI decrease from baseline at the end of treatment (EOT) had a statistically significant improvement in PFS. Interestingly, a similar BMI/weight decrease within the first 8 weeks of therapy identified patients at higher risk of progression.

Patients and methods

we performed a retrospective analysis of patients enrolled in the BALLET trial who progressed durin

SUBMITTER: Corona SP 

PROVIDER: S-EPMC7289535 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature